962 related articles for article (PubMed ID: 25586660)
21. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
22. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
Neunert CE
Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
[TBL] [Abstract][Full Text] [Related]
24. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
25. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
26. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
[TBL] [Abstract][Full Text] [Related]
27. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
[TBL] [Abstract][Full Text] [Related]
28. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
[No Abstract] [Full Text] [Related]
29. Moving towards a new era in the management of chronic immune thrombocytopenia.
Wadenvik H; Olsson B
Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
[TBL] [Abstract][Full Text] [Related]
30. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
31. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
32. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
J Pediatr; 2014 Sep; 165(3):600-5.e4. PubMed ID: 24857517
[TBL] [Abstract][Full Text] [Related]
33. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
34. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Vibor M; Rogulj IM; Ostojic SK
Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
Meyer O; Richter H; Lebioda A; Schill M
Hematology; 2021 Dec; 26(1):697-708. PubMed ID: 34547980
[TBL] [Abstract][Full Text] [Related]
36. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Zeng Y; Duan X; Xu J; Ni X
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
[TBL] [Abstract][Full Text] [Related]
38. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Ghadaki B; Nazi I; Kelton JG; Arnold DM
Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
[TBL] [Abstract][Full Text] [Related]
39. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.
Forsythe A; Schneider J; Pham T; Bhor M; Said Q; Allepuz A; Socorro O Portella MD; Kwon CS; Roy AN
J Comp Eff Res; 2020 May; 9(7):447-457. PubMed ID: 32175766
[No Abstract] [Full Text] [Related]
40. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
Cooper N; Hill QA; Grainger J; Westwood JP; Bradbury C; Provan D; Thachil J; Ramscar N; Roy A
Acta Haematol; 2021; 144(4):418-426. PubMed ID: 33789275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
